Covid-19

#Big pharma #Biopharmaceuticals #Biotechnology #Covid-19 #Vaccines

Supply chains key to successful COVID-19 vaccine roll-out 

Resilience in pharma and biotech supply chains is essential for the roll out of the Covid-19 vaccine, says Karl Lauri, ERP/MRP software manufacturer and distributor MRPeasy.com.  While the pandemic has highlighted the strength of the UK’s pharmaceutical and biotechnology sector, it has also shed light on the vulnerabilities of intricate, geographically extended and… Read More

#Covid-19 #News

#Assay development optimisation & technology #Covid-19 #Immunology / Virology & Vaccines

Bio-Rad launches new SARS-CoV-2 serology assay panel

Bio-Rad’s Bio-Plex Pro Human IgG SARS-CoV-2 N/RBD/S1/S2 4-Plex Panel is a ready-to-use, qualitative multiplex immunoassay panel which has been designed to provide quick, precise detection of IgG antibodies against four SARS-CoV-2 antigens. This “provides useful information about natural exposure rates in a population or about vaccine immunogenicity,” said Candice Cox,… Read More

#Covid-19 #News

#Covid-19 #Life sciences

Bruntwood SciTech acquires new science park in the Golden Triangle for £46.2m

Property provider Bruntwood SciTech, dedicated to the growth of the science and technological sector, has expanded into the “Golden Triangle” through the acquisition of Melbourn Science Park from independent technology and product development company TTP for £46.2 million. Bruntwood SciTech will work closely with the local planning authority to develop… Read More

#Editor's Choice #News

#Biopharmaceuticals #Covid-19 #Podcast #Therapeutics

How critical is the part therapeutics in the COVID-19 pandemic? – podcast

The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma. RedHill Biopharma  is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19… Read More

#Covid-19 #Editor's Choice #News

#Coronavirus #Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Pandemic #Sitting Down With #Therapeutics

How critical is the part therapeutics have to play in the pandemic?

This DDW Sponsored Sitting Down With episode features Guy Goldberg, Chief Business Officer of RedHill Biopharma. In this episode  – Guy Goldberg discusses COVID-19 therapeutics and their role in the pandemic. Goldberg shares his market insight, the benefits of an orally-administered small molecule tablet for COVID treatment and how the… Read More

#Podcasts

#Anti-virals #Covid-19 #Interferons #Therapeutics

Inventor of synthetic Interferon discusses potential against COVID-19

ILC Therapeutics, a biotech company based in Scotland, is developing a synthetic Interferon which has shown great promise against COVID-19 in laboratory testing and will enter clinical trials later this year. It will be, says the company, the first synthetic Interferon based on the most prominent activities of the natural… Read More

#Covid-19 #Editor's Choice #Exclusive Content #Opinion

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

COVID-19 vaccine pill a possibility?

Professor Sarah Gilbert, head of the team behind the Oxford AstraZeneca COVID-19 vaccine, has told UK MPs that there is a possibility the vaccine could be taken orally and perhaps also via a nasal spray. Reported in The Guardian newspaper today, she was asked by MP Graham Stringer how the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biotechnology #Coronavirus #Covid-19 #Drug development #Drug discovery #Metabolomics #Metabolon #Narrated podcasts #Pharmaceutical

The potential of metabolomics & COVID-19 Vaccine Development

Today’s episode is titled The potential of metabolomics & COVID-19 Vaccine Development, and covers 2 articles taken from the most recent Fall issue of DDW. These articles are titled: Why metabolomics has the potential to transform diagnosis and treatment. & COVID-19 Vaccine Development: dethroning evil King Coronavirus These articles were firstly… Read More

#Podcasts

#Covid-19 #Immunology / Virology & Vaccines

Pfizer and AstraZeneca COVID-19 vaccine working, suggests Scottish study

The study is the first to describe across an entire country the effect of the Pfizer and Oxford-AstraZeneca jabs in the community on preventing severe illness resulting in hospitalisation. Previous results about vaccine efficacy have come from clinical trials. Hospitalisation drop By the fourth week after receiving the initial dose,… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Sanofi and GSK start new Phase II study of their COVID-19 vaccine candidate

Sanofi and GlaxoSmithKline (GSK) have begun a new Phase II study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase III evaluation of their adjuvanted recombinant protein COVID-19 vaccine candidate. “Over the past few weeks, our teams have worked to refine the antigen… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Biopharmaceuticals #Covid-19 #Therapeutics

RedHill Biopharma: first patient dosed in US Phase II/III COVID-19 RHB-107 study

RedHill Biopharma, a specialty biopharmaceutical company, has announced that the first patient was dosed in its US Phase II/III study of orally-administered RHB-107 (upamostat)[i], an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care. Dror Ben-Asher, RedHill’s CEO said: “RedHill is rapidly advancing two Phase… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Human trials #Immunology / Virology & Vaccines

World’s first coronavirus Human Challenge study receives ethics approval

The UK will be the first country in the world to run a COVID-19 human challenge study, following approval from the UK’s clinical trials ethics body. Backed by a £33.6 million UK government investment, the first-of-its-kind study for this virus will involve establishing the smallest amount of virus needed to… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Covid-19 #Diagnostics #Drug development

BioIVT unveils COVID-19 panel to boost vaccine-generated immune response research

BioIVT, provider of research models and services for drug and diagnostic development, has introduced its COVID-19 Vaccination Panel, composed of pre- and post-vaccination serum or PBMC samples, to enable researchers to study blood donors’ vaccine-generated immune response. BioIVT has been providing more than 300 clients with biospecimens to support the… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines

World Health Organization experts provide guidance on use of the Oxford vaccine

The World Health Organization (WHO) Strategic Advisory Group of Experts (SAGE) has produced guidelines for the emergency use of the ChAdOx1 nCoV-19 coronavirus vaccine developed by the University of Oxford with its partner AstraZeneca. The WHO has recommended that two standard doses of ChAdOx1 nCoV-19 be administered at an 8-… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

Recruitment begins for Phase III trial of Janssen’s COVID-19 vaccine candidate

The University of Kentucky has been selected as a testing site for the Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III clinical research study ENSEMBLE 2, which is evaluating the safety and efficacy of a two-dose regimen of Janssen’s COVID-19 vaccine candidate. The Phase III ENSEMBLE 2 study is… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine data on protection against COVID-19 infection from South African variant

In an analysis, submitted as a pre-print prior to peer-review publication, a two-dose regimen of the ChAdOx1 nCoV-19 vaccine provides minimal protection against mild-moderate COVID-19 infection from the B.1.351 coronavirus variant first identified in South Africa. Efficacy against severe COVID-19 infection from this variant was not assessed. The analyses being… Read More

#Covid-19 #News #Trending News